Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- 16 May 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 10 (6), 520-529
- https://doi.org/10.1016/s1474-4422(11)70099-0
Abstract
No abstract availableFunding Information
- Novartis
This publication has 9 references indexed in Scilit:
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year resultsMultiple Sclerosis Journal, 2009
- Oral fingolimod (FTY720) in multiple sclerosisNeurology, 2009
- Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisNeurology, 2008
- Oral Fingolimod (FTY720) for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change AnalysisNeuroImage, 2002
- Rating neurologic impairment in multiple sclerosisNeurology, 1983